These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 28233748

  • 1. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J, Kedarisetty C, Venkataraman J, Srinivasan V, Deepashree T, Uthappa M, Ilankumaran K, Govil S, Reddy M, Rela M.
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [Abstract] [Full Text] [Related]

  • 2. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y, Chen B, Liu N, Li N, Dao H, Chen W, Yang J.
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [Abstract] [Full Text] [Related]

  • 3. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F.
    Oncotarget; 2016 Dec 13; 7(50):83806-83816. PubMed ID: 27566566
    [Abstract] [Full Text] [Related]

  • 4. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 13; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 5. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.
    World J Gastroenterol; 2014 Jan 21; 20(3):786-94. PubMed ID: 24574751
    [Abstract] [Full Text] [Related]

  • 6. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
    Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho RT.
    Ann Oncol; 2013 Apr 21; 24 Suppl 2():ii24-9. PubMed ID: 23715940
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C.
    J BUON; 2017 Apr 21; 22(1):150-156. PubMed ID: 28365948
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY.
    Int J Cancer; 2015 Mar 15; 136(6):1458-67. PubMed ID: 25099027
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P.
    BMC Cancer; 2015 May 11; 15():392. PubMed ID: 25957784
    [Abstract] [Full Text] [Related]

  • 12. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ.
    BMC Cancer; 2017 Sep 12; 17(1):645. PubMed ID: 28899349
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Romero G, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Reggiardo V, Colombato L, Gadano A, Silva M.
    World J Gastroenterol; 2019 Jul 21; 25(27):3607-3618. PubMed ID: 31367160
    [Abstract] [Full Text] [Related]

  • 15. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L.
    BMC Gastroenterol; 2018 Sep 04; 18(1):138. PubMed ID: 30180810
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
    Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH.
    Ann Oncol; 2013 Jul 04; 24(7):1786-1792. PubMed ID: 23508822
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Zhang K, Sun X, Xie F, Jian W, Li C.
    J Cancer Res Ther; 2018 Jan 04; 14(1):196-200. PubMed ID: 29516985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.